Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8726
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer ; day:16 ; month:3 ; year:2018 ; pages:1-7
World journal of urology ; (16.3.2018), 1-7
- Urheber
-
Soria, Francesco
- Beteiligte Personen und Organisationen
-
Beleni, Andrea I.
D'Andrea, David
Resch, Irene
Gust, Kilian M.
Gontero, Paolo
Shariat, Shahrokh F.
SpringerLink (Online service)
- DOI
-
10.1007/s00345-018-2264-0
- URN
-
urn:nbn:de:1111-201805204167
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Soria, Francesco
- Beleni, Andrea I.
- D'Andrea, David
- Resch, Irene
- Gust, Kilian M.
- Gontero, Paolo
- Shariat, Shahrokh F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis